Innovent Biologics
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies.
Launch date
Employees
Market cap
€7.9b
Enterprise valuation
€7.1b (Public information from Sep 2024)
Share price
HKD42.65 1801.HK
Suzhou Shi Jiangsu (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 3.8b | 4.3b | 4.6b | 6.2b | 7.9b | 10.3b | 13.3b |
% growth | 267 % | 11 % | 7 % | 36 % | 27 % | 30 % | 29 % |
EBITDA | (735m) | (2.9b) | (1.8b) | (691m) | (630m) | 412m | 1.8b |
% EBITDA margin | (19 %) | (68 %) | (39 %) | (11 %) | (8 %) | 4 % | 13 % |
Profit | (998m) | (3.1b) | (2.2b) | (1.0b) | (860m) | 22.9m | 1.3b |
% profit margin | (26 %) | (73 %) | (48 %) | (17 %) | (11 %) | - | 10 % |
EV / revenue | 23.4x | 11.9x | 8.7x | 9.1x | 7.3x | 5.7x | 4.4x |
EV / EBITDA | -122.3x | -17.5x | -22.5x | -81.7x | -91.9x | 141.6x | 32.9x |
R&D budget | 1.9b | 2.5b | 2.9b | 2.2b | - | - | - |
R&D % of revenue | 48 % | 58 % | 63 % | 36 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$5.0m | Series A | ||
$25.0m | Series B | ||
$115m | Series C | ||
* | $260m | Series D | |
$150m Valuation: $1.0b | Series E | ||
N/A | $421m Valuation: $2.0b | IPO | |
* | N/A | €300m | Post IPO Equity |
Total Funding | €505m |
Related Content
Recent News about Innovent Biologics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Innovent Biologics
EditACQUISITION by Nuvation Bio Mar 2024